Grace Science
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
873 Santa Cruz Ave Ste 200, Menlo Park, ...Website
www.gracescience.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Grace Science
Grace Science, LLC is dedicated to understanding and addressing NGLY1 deficiency and its implications for human health. The company employs a multidisciplinary team of experts to develop innovative gene therapies and small molecule programs targeting oncology and neurodegeneration. Their mission is driven by a commitment to patients, particularly those affected by rare diseases, and aims to create effective treatments that can benefit millions. Through collaboration and cutting-edge research, Grace Science seeks to unlock new pathways for drug development and improve the lives of those impacted by NGLY1 deficiency.Explore more
Grace Science Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Grace Science your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Grace Science has recently received funding, and reach out quickly before it becomes old news!
Grace Science, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Grace Science launches new products
Funding: Get notified immidiatlly once Grace Science has new funding data
Check out if Grace Science is spiking on competitors!
Earning: See what the market has to say on Grace Science recently announced quarterly report
Click to see if Grace Science had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Grace Science
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Grace Science
Find more new buyers
Compare Similar Companies to Grace Science
Compare insights from companies similar to Grace Science, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Grace Science is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Grace Science is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Grace Science.
Grace Science Tech Stack
A closer look at the technologies used by Grace Science
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Person-Based
Matthew Wilsey, Chief Executive Officer, appeared on a podcast called "Raising Health" on 12/10/2024. Topics discussed include Rare disease, biotech startup, gene therapy.
Events, Podcast
Partnership
Partnership, Research & Development, Medical Research
Partnership
Grace Science News & Media
Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency
COLUMBUS, Ohio, March 25, 2024 /PRNewswire/ -- Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process...Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency
MENLO PARK, Calif.--(BUSINESS WIRE)--Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency. Part 1/2 of the study will investigate dose-escalation and the safety and efficacy of a single intracerebroventricular (ICV) infusion of GS-100 in NGLY1 Deficiency patients aged 2-18 years. Part 3 of the study will assess the co-primary outcomes at 52 weeks
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Grace Science
Sign Up For FreeTo access detailed company insights
Grace Science, LLC is dedicated to understanding and addressing NGLY1 deficiency and its implications for human health. The company employs a multidisciplinary team of experts to develop innovative gene therapies and small molecule programs targeting oncology and neurodegeneration. Their mission is driven by a commitment to patients, particularly t... Read More
